These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20095432)

  • 41. [Immunogenicity and safety of vaccine preparations based on circulating Bordetella pertussis strains].
    Zaĭtsev EM; Mertsalova NIu; Britsina MV; Ozeretskovskaia MN; Bazhanova IG; Shinkarev AS; Poddubikov AV
    Zh Mikrobiol Epidemiol Immunobiol; 2014; (4):18-22. PubMed ID: 25286523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Molecular genetic characteristics of the B. pertussis strains isolated in different periods of the pertussis epidemic process].
    Mazurova IK; Borisova OIu; Kombarova SIu; Zakharova NS; Aleshkin VA
    Mol Gen Mikrobiol Virusol; 2005; (4):21-5. PubMed ID: 16334221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.
    Taranger J; Trollfors B; Bergfors E; Knutsson N; Lagergård T; Schneerson R; Robbins JB
    Pediatrics; 2001 Dec; 108(6):E115. PubMed ID: 11731642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serospecific protection of mice against intranasal infection with Bordetella pertussis.
    Robinson A; Gorringe AR; Funnell SG; Fernandez M
    Vaccine; 1989 Aug; 7(4):321-4. PubMed ID: 2573215
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do we need a new vaccine to control the re-emergence of pertussis?
    Mills KH; Ross PJ; Allen AC; Wilk MM
    Trends Microbiol; 2014 Feb; 22(2):49-52. PubMed ID: 24485284
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice.
    Feunou PF; Kammoun H; Debrie AS; Locht C
    Vaccine; 2014 Jul; 32(34):4281-8. PubMed ID: 24950361
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Application of DNA microcarriers for evaluation of mice splenocytes genes expression after immunization with pertussis vaccines and challenged with different B. pertussis strains].
    Gzyl A; Woyciechowska-Oczko M; Jarzab B; Augustynowicz E; Mosiej E; Slusarczyk J
    Med Dosw Mikrobiol; 2007; 59(2):149-59. PubMed ID: 17929412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.
    Thorstensson R; Trollfors B; Al-Tawil N; Jahnmatz M; Bergström J; Ljungman M; Törner A; Wehlin L; Van Broekhoven A; Bosman F; Debrie AS; Mielcarek N; Locht C
    PLoS One; 2014; 9(1):e83449. PubMed ID: 24421886
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of peptides that mimic the pertussis toxin binding site on bovine fetuin.
    Bogdan JA; Yuan W; Long-Rowe KO; Sarwar J; Brucker EA; Blake MS
    Appl Environ Microbiol; 2003 Oct; 69(10):6272-9. PubMed ID: 14532091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines.
    Seubert A; D'Oro U; Scarselli M; Pizza M
    Expert Rev Vaccines; 2014 Oct; 13(10):1191-204. PubMed ID: 25183193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against
    Zurita ME; Wilk MM; Carriquiriborde F; Bartel E; Moreno G; Misiak A; Mills KHG; Hozbor D
    Front Cell Infect Microbiol; 2019; 9():125. PubMed ID: 31106160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.
    Vandebriel RJ; Gremmer ER; Vermeulen JP; Hellwig SM; Dormans JA; Roholl PJ; Mooi FR
    Vaccine; 2007 Mar; 25(12):2346-60. PubMed ID: 17224216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
    Hegerle N; Guiso N
    Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PTX Instructs the Development of Lung-Resident Memory T Cells in
    Tomas J; Koo Y; Popoff D; Arce-Gorvel V; Hanniffy S; Gorvel JP; Mionnet C
    Toxins (Basel); 2021 Sep; 13(9):. PubMed ID: 34564636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of pertussigen (pertussis toxin) on the mouse protective activity of vaccines made from Bordetella species.
    Munoz JJ; Peacock MG
    Microbiol Immunol; 1989; 33(4):341-55. PubMed ID: 2549344
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model.
    Cheung GY; Xing D; Prior S; Corbel MJ; Parton R; Coote JG
    Infect Immun; 2006 Dec; 74(12):6797-805. PubMed ID: 16982827
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against Bordetella pertussis Disease and Infection.
    Locht C; Papin JF; Lecher S; Debrie AS; Thalen M; Solovay K; Rubin K; Mielcarek N
    J Infect Dis; 2017 Jul; 216(1):117-124. PubMed ID: 28535276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response.
    Rappuoli R; Pizza M; Covacci A; Bartoloni A; Nencioni L; Podda A; De Magistris MT
    FEMS Microbiol Immunol; 1992 Oct; 5(4):161-70. PubMed ID: 1384602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.